^
    3d
    Targeting Bruton tyrosine kinase with acalabrutinib attenuates murine sclerodermatous chronic graft versus host disease. (PubMed, Front Immunol)
    RNA-seq analysis of skin identified genes associated with keratinization that were downregulated with acalabrutinib treatment. Our results demonstrate that specific inhibition of BTK with acalabrutinib has a potentially beneficial role in ameliorating sclerodermatous cGVHD by improving the survival and clinical benefits and warrants further investigation in patients with cGVHD.
    Preclinical • Journal
    |
    BTK (Bruton Tyrosine Kinase) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • CCL2 (Chemokine (C-C motif) ligand 2) • CCL22 (C-C Motif Chemokine Ligand 22) • CCL3 (C-C Motif Chemokine Ligand 3)
    |
    Calquence (acalabrutinib)
    3d
    ARCHED: Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P3, N=330, Recruiting, Universitt des Saarlandes | Trial primary completion date: Apr 2028 --> Feb 2029
    Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6) • IRF4 (Interferon regulatory factor 4)
    |
    Rituxan (rituximab) • cyclophosphamide • Calquence (acalabrutinib) • vincristine • prednisolone
    4d
    A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies (clinicaltrials.gov)
    P1, N=35, Completed, AstraZeneca | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Sep 2025
    Trial completion • Trial completion date
    |
    Gazyva (obinutuzumab) • Calquence (acalabrutinib)
    11d
    CARAMEL: Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=48, Active, not recruiting, University College, London | Recruiting --> Active, not recruiting | Trial completion date: Dec 2028 --> Jun 2028 | Trial primary completion date: Nov 2026 --> Jun 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    CCND1 (Cyclin D1)
    |
    Chr t(11;14)
    |
    Rituxan (rituximab) • Calquence (acalabrutinib)
    15d
    Acalabrutinib in CNSL (clinicaltrials.gov)
    P1/2, N=49, Active, not recruiting, Dana-Farber Cancer Institute | Trial primary completion date: Apr 2026 --> Nov 2025
    Trial primary completion date
    |
    Calquence (acalabrutinib)
    15d
    Outcomes From the Multicenter ACCRU-LY-1804/CARiBOU TRIAL (Cytarabine, Acalabrutinib and Rituximab Integrated With Bortezomib-Based Outpatient Therapy) in 1st Line Mantle Cell Lymphoma. (PubMed, Am J Hematol)
    This multitargeted regimen addresses the biologic heterogeneity of MCL and permits flexible MRD-guided decisions on consolidation and maintenance. Trial Registration: ClinicalTrials.gov identifier: NCT04626791.
    Journal
    |
    clonoSEQ®
    |
    Rituxan (rituximab) • cytarabine • bortezomib • Calquence (acalabrutinib)
    15d
    19-C-0116: Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=132, Recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2030 --> Mar 2031 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Calquence (acalabrutinib)
    20d
    Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Gazyva (obinutuzumab) • Calquence (acalabrutinib)
    20d
    Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=105, Active, not recruiting, University Health Network, Toronto | Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2023 --> Sep 2028
    Enrollment closed • Trial primary completion date
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Calquence (acalabrutinib)
    21d
    Indirect Comparison of the Efficacy of Zanubrutinib vs Ibrutinib and Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-Up. (PubMed, Adv Ther)
    These findings inform the long-term comparative efficacy of Bruton tyrosine kinase inhibitors and suggest that zanubrutinib may confer sustained PFS and OS benefits compared with ibrutinib and acalabrutinib in similar treatment-naive CLL populations. Graphical abstract and video available for this article. Overview of the Comparative Efficacy of Covalent BTK Inhibitors in Treatment-Naïve CLL/SLL With Six-Year Follow-Up (MP4 345006 kb).
    Journal
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    Imbruvica (ibrutinib) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib)
    22d
    From Solid Organ Malignancies to Dual Leukaemias: Sequential CLL and CML in a Cancer Survivor. (PubMed, Eur J Case Rep Intern Med)
    Chronic lymphocytic leukaemia (CLL) most commonly transforms into aggressive lymphoma; development of chronic myeloid leukaemia (CML) in a patient with CLL should prompt evaluation for an independent myeloid clone rather than presumed transformation.Myeloid neoplasms in patients with CLL may arise from therapy-related leukemogenesis or divergent evolution from a shared hematopoietic progenitor, highlighting the importance of molecular characterization.Management of coexisting CLL and CML requires individualized risk-benefit assessment, particularly in elderly patients with prior solid tumours and immune dysfunction.
    Journal
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    Imbruvica (ibrutinib) • imatinib • Calquence (acalabrutinib) • Scemblix (asciminib)
    23d
    AB-HLA-2026: Acalabrutinib Maleate and Bortezomib for Patients With HLA Antibodies (clinicaltrials.gov)
    P3, N=42, Not yet recruiting, The First Affiliated Hospital of Soochow University
    New P3 trial
    |
    bortezomib • Calquence (acalabrutinib)